Last reviewed 2026-04-20 · How we verify

Vaccine Candidate #6

At a glance

Approved indications

No approved indications tracked.

Common side effects

• Pain
• Fatigue
• Headache
• Upper respiratory tract infection
• Swelling
• Redness
• Malaise
• Pyrexia
• Injection site pain
• Arthralgia
• Myalgia
• Decreased appetite

Key clinical trials

• A Study to Learn About a Modified RNA Vaccine Against Shingles in Healthy Adults (PHASE1, PHASE2)
• First-in-Human PfSPZ-LARC2 Vaccination/CHMI (PHASE1)
• Testing RG1-VLP Vaccine to Prevent HPV-related Cancers (PHASE1)
• A Safety, Immunogenicity and Efficacy Study of PvRII/Matrix-M in Healthy Thai Adults Living in Thailand ( MIST3 ) (PHASE2)
• Personalized Immunotherapy in Adults With Advanced Cancers Immunotherapy in Adults With Advanced Cancers (PHASE1)
• A Study to Learn About mRNA Vaccines Against Influenza in Adults (PHASE2)
• Phase 1/2 Study of a Plant-Based Seasonal Recombinant Trivalent VLP Influenza Vaccine (PHASE1, PHASE2)
• A Study to Assess the Experimental Malaria Vaccines RH5.2-VLP and R21 (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Vaccine Candidate #6 CI brief — competitive landscape report
• Vaccine Candidate #6 updates RSS · CI watch RSS
• Pfizer portfolio CI